Eli Lilly and Company
For nearly 150 years, we’ve made significant and game-changing progress on our mission to make life better for people around the world. We’ve remained headquartered in Indianapolis, Indiana, since our founding on May 10, 1876, but our employees now work in countries around the world.
And thanks to the dedication of our diverse global team, we’ve been able to answer the call for new medicines to help solve some of the world’s most significant health challenges
When you’re on a mission to do what’s never been done before, you seek people willing to challenge the status quo of medicine. Those willing to relentlessly pursue what’s next, all in the name of health above all. #WeAreLilly
We are Lilly
Why do our employees love coming to work each and every day? Here’s what they have to say.
47,000 global employees coming together from diverse backgrounds to create medicines that make life better for people around the world. Get to know Team Lilly through our Powered by Purpose series.
NEWS
Biopharma has several unique challenges, but one of them is the patent cliff. In an industry where only about one in 10 compounds actually makes it to market on average, those drugs aren’t able to stay on the market very long before their patents end and generic competition begins.
For those select few who achieve the role of chief executive officer of a multi-national corporation, the compensation packages are typically quite large – especially when compared to the average salaries of company employees.
The company indicated it was dropping LY2606368, prexasertib, a CHK1 drug in Phase II, and LY3023414, a PI3k/mTOR inhibitor that was also in Phase II.
According to a recent BioSpace survey, 93% of respondents are open to a new job for the right opportunity. Are you one of the 93%? If so, keep your eyes open for those opportunities and don’t stop looking. You never know what may come your way!
Eli Lilly and Company announced that as it withdraws Lartruvo (olaratumab) from the market for treatment of advanced soft tissue sarcoma (STS), it is establishing an Access Program for patients currently receiving the drug who may wish to continue.
Eddingpharm forked over $375 million for the rights to sell Ceclor and Vancocin in China, as well as a manufacturing facility that makes the two medications.
The two companies will combine their expertise to drive new immunology candidates toward the clinic.
Eli Lilly and Company announced results from its COAST-X Phase III clinical trial of Taltz (ixekizumab) in non-radiographic axial spondyloarthritis (nr-axSpA) in patients who had no previous disease-modifying anti-rheumatic drug (bDMARD) treatment.
Pfizer and Eli Lilly and Company announced top-line results from a Phase III clinical trial of two doses of tanezumab in moderate-to-severe osteoarthritis (OA) of the hip or knee.
JOBS
IN THE PRESS